1. NICM home
  2. Research
  3. Clinical Trials
  4. Endometriosis Study

Endometriosis Study

Do you experience endometriosis related pain and fatigue?

Endometriosis affects over 360,000 Australians and is the most common cause of chronic pelvic pain for women. Current non-surgical treatments such as non-steroidal anti-inflammatories, oral contraceptive pills and hormonal treatments have limited effectiveness and the side-effect profile can be troublesome for many women.

NICM researchers are seeking participants to be involved in a clinical trial examining the effectiveness of a modified traditional Chinese herbal medicine for endometriosis related pain and fatigue.

Who can join?

  • Women aged 18-45 years living in Australia.
  • Women who:
    • Have a confirmed diagnosis of endometriosis via laparoscopy in the last five years.
    • Have moderate to severe pelvic pain on a regular basis.
    • Are not pregnant, breastfeeding or planning to become pregnant in the next three months.
    • Have not had surgery on your abdomen in the last six months.
    • Have not started or stopped any treatments for your endometriosis in the last six months.

What's involved?

  • After an initial assessment and consent, you will:
    • Complete a short online diary once a day for a month, to evaluate your eligibility to participate in this clinical trial and to assess your current level of endometriosis related pain.
    • Have blood taken to assess your liver and kidney function.
  • Participants will be randomly allocated into a treatment group (active or placebo). Over the three-month study, participants will be asked to:
    • Take six capsules per day.
    • Complete a short online diary form once a day.
  • After treatment:
    • Have blood taken.
    • Complete a short online questionnaire one month after the last capsule.

What are the benefits of participating?

  • If you currently experience endometriosis related chronic pelvic pain you may get a reduction in either your pelvic pain or fatigue from taking the study medication.
  • Once you have completed the study, and if you were in the placebo group, you are eligible to receive a three month complimentary supply of the active treatment.

For more details about this study please read the following information before deciding on whether to participate or not.

Interested in participating in this study?

In order to confirm your eligibility and register your interest, please complete the online screening form below.

For more information please contact:

Mahmoud Al-Dabbas
NICM Research Officer
e. m.al-dabbas@westernsydney.edu.au
p. (02) 9685 4736
m. 0414 357 363

Human Research Ethics Committee Approval: This clinical trial has been approved by Western Sydney University Human Research Ethics Committee (Approval Number: H13256).

This study is supported by a Partnership Grant between Metagenics and Western Sydney University.

Chief Investigator: Dr Mike Armour, NICM Health Research Institute